Crowdonomics
WatchlistPortfolio
All companies
Cizzle Bio, Inc. logo

Cizzle Bio, Inc.

Operating

Biotech · San Antonio, TX

Visit website
Post-money valuation ⓘ
$70.5M
As of Apr 2026 · from Reg CF Offering (2024) · pre-money + amount raised, not a traded price
Total raised
$2,764,650
Crowd $15K · Private $2.8M · 3 rounds since 2024
Latest share price
$0.38
Reg CF · Common Stock · Nov 2024 offering price

Financials

FY2022–FY2023 · from SEC filings · hover any figure for its source
$0
2022
$0
−$440K
2023
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2022 audited
FY2023 audited
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
$0
-$439,818
Taxes paid
$0
$0
Balance sheet
Cash
$0
$845,048
Accounts receivable
$0
$0
Total assets
$0
$845,048
Short-term debt
$0
$42,409
Long-term debt
$0
$1,228,500
Total liabilities
$0
$1,270,909
Other
Headcount
—
0

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$70.5M
pre-money
Reg CF · Common · Nov 2024

Blue bars are the pre-money valuation the company stated for a priced round.

Share price over rounds

$0.38$0.19$0.38
Jan 2024Nov 2024
Round offering price or verified disclosed saleDisclosed sale, unverified or year-only

Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.

Fundraising history

Reg CF · Common Stock · Nov 2024Closedvia DealMaker
Raised $14.7K / $5MPost-money $70.5M
Section 4(a)(2) · SAFEs shares of Class A Voting Common Stock. · Jan 2024Closed
Raised $2.5M

Team

1 person
/s/ William Behnke
Chief Executive Officer

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 2 annual reports (FY2024–FY2025)

Missing: 2024, 2025

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C-USep 19, 20250001062993-25-015723
    EDGAR
  • Form C/AApr 17, 20250001062993-25-007617
    EDGAR
  • Form C/AApr 17, 20250001062993-25-007622
    EDGAR
  • Form C/AFeb 3, 20250001062993-25-001432
    EDGAR
  • Form CNov 4, 20240001062993-24-018218
    EDGAR
  • Form C/ANov 4, 20240001062993-24-018237
    EDGAR
Source: SEC EDGARCIK 0002043459TXShare price $0.38Last synced Aug 17, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.